|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5567584A
(en)
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
|
US20020099179A1
(en)
|
1989-12-21 |
2002-07-25 |
Linda K. Jolliffe |
Cdr-grafted antibodies
|
|
DK261490D0
(da)
|
1990-10-31 |
1990-10-31 |
Novo Nordisk As |
New pharmaceutical compound
|
|
US6165467A
(en)
|
1991-07-20 |
2000-12-26 |
Yoshihide Hagiwara |
Stabilized human monoclonal antibody preparation
|
|
US5789192A
(en)
|
1992-12-10 |
1998-08-04 |
Schering Corporation |
Mammalian receptors for interleukin-10 (IL-10)
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
JP3681206B2
(ja)
|
1995-12-26 |
2005-08-10 |
株式会社三菱化学ヤトロン |
抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
|
|
KR100374737B1
(ko)
|
1996-06-28 |
2003-07-16 |
세이코 엡슨 가부시키가이샤 |
트랜지스터형성방법,그트랜지스터를포함하는회로,액티브매트릭스기판의제조방법,표시장치의제조방법,및프로젝터및전자기기
|
|
US5985614A
(en)
|
1996-08-30 |
1999-11-16 |
Human Genome Sciences, Inc. |
Polynucleotides encoding interleukin-19
|
|
ATE424410T1
(de)
|
1996-08-30 |
2009-03-15 |
Human Genome Sciences Inc |
Interleukin-19.
|
|
US5945511A
(en)
|
1997-02-20 |
1999-08-31 |
Zymogenetics, Inc. |
Class II cytokine receptor
|
|
EP0981548A4
(en)
|
1997-04-30 |
2005-11-23 |
Enzon Inc |
GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF
|
|
US6486301B1
(en)
|
1997-07-16 |
2002-11-26 |
Human Genome Sciences, Inc. |
Interleukin-20
|
|
AU8571198A
(en)
|
1997-07-16 |
1999-02-10 |
Human Genome Sciences, Inc. |
Interleukin-20
|
|
AU8899298A
(en)
|
1997-08-06 |
1999-03-01 |
Zymogenetics Inc. |
Lipocalin homologs
|
|
US6576743B1
(en)
|
1997-11-26 |
2003-06-10 |
Zymogenetics, Inc. |
Mammalian cytokine-like polypeptide-10
|
|
EP1047781B1
(en)
|
1998-01-23 |
2004-07-28 |
Immunex Corporation |
Il-18 receptors
|
|
WO1999046379A2
(en)
|
1998-03-09 |
1999-09-16 |
Schering Corporation |
Human receptor proteins; related reagents and methods
|
|
JP3868740B2
(ja)
|
1998-03-10 |
2007-01-17 |
ジェネンテック・インコーポレーテッド |
新規なポリペプチド及びそれをコードする核酸
|
|
US7198789B2
(en)
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
CN1233476A
(zh)
|
1998-04-24 |
1999-11-03 |
陆道培 |
治疗急性白血病的药物及其制备方法
|
|
AU5203199A
(en)
|
1998-05-26 |
1999-12-13 |
Procter & Gamble Company, The |
Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
|
|
AU4411699A
(en)
|
1998-06-05 |
1999-12-20 |
Human Genome Sciences, Inc. |
Interferon receptor hkaef92
|
|
US7041805B2
(en)
|
1998-09-01 |
2006-05-09 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
CN1317967A
(zh)
*
|
1998-09-17 |
2001-10-17 |
伊莱利利公司 |
蛋白质制剂
|
|
US7087215B2
(en)
*
|
1998-12-21 |
2006-08-08 |
Generex Pharmaceuticals Incorporated |
Methods of administering and enhancing absorption of pharmaceutical agents
|
|
US6451286B1
(en)
*
|
1998-12-21 |
2002-09-17 |
Generex Pharmaceuticals Incorporated |
Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
|
|
EP1141008A1
(en)
|
1998-12-31 |
2001-10-10 |
Millennium Pharmaceuticals, Inc. |
Class ii cytokine receptor-like proteins and nucleic acids encoding them
|
|
ATE478145T1
(de)
|
1999-06-02 |
2010-09-15 |
Genentech Inc |
Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
|
|
US20050060101A1
(en)
|
1999-06-28 |
2005-03-17 |
Bevilacqua Michael P. |
Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
|
|
DE60031999T2
(de)
|
1999-10-04 |
2007-06-06 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
|
|
KR100399156B1
(ko)
*
|
1999-11-19 |
2003-09-26 |
주식회사 엘지생명과학 |
α-인터페론의 용액제형
|
|
JP4741139B2
(ja)
|
1999-12-23 |
2011-08-03 |
ザイモジェネティクス， インコーポレイテッド |
可溶性インターロイキン−２０レセプター
|
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
|
US6977169B2
(en)
|
2000-04-07 |
2005-12-20 |
Kline Ellis L |
Methods and compositions for treating neoplasms
|
|
US7015194B2
(en)
|
2000-05-10 |
2006-03-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising factor VIIa and anti-TFPI
|
|
WO2002011753A1
(en)
|
2000-08-04 |
2002-02-14 |
Chugai Seiyaku Kabushiki Kaisha |
Protein injection preparations
|
|
ES2381650T3
(es)
|
2000-08-08 |
2012-05-30 |
Zymogenetics, Inc. |
Receptores de citoquinas Zcytor11 solubles
|
|
US8632778B2
(en)
|
2000-08-11 |
2014-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized anti-interleukin-6 antibody-containing preparations
|
|
AU2002213441B2
(en)
|
2000-10-12 |
2006-10-26 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
WO2002070001A2
(en)
|
2001-02-28 |
2002-09-12 |
Eli Lilly And Company |
Use of lp82 to treat hematopoietic disorders
|
|
AU2002245652A1
(en)
|
2001-03-09 |
2002-09-24 |
Zymogenetics, Inc. |
Soluble heterodimeric cytokine receptor
|
|
CA2454587C
(en)
|
2001-07-25 |
2012-11-13 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
|
ES2629395T3
(es)
|
2001-10-04 |
2017-08-09 |
Genetics Institute, Llc |
Métodos y composiciones para modular la actividad de la interleucina-21
|
|
US7022289B1
(en)
|
2001-10-10 |
2006-04-04 |
The United States Of America As Represented By The Secretary Of The Army |
Chemical and biological sampling device and kit and method of use thereof
|
|
BRPI0214168B8
(pt)
*
|
2001-11-14 |
2021-05-25 |
Centocor Inc |
anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
|
|
CA2467723C
(en)
|
2001-12-17 |
2011-09-27 |
Zymogenetics, Inc. |
Method for treating cervical cancer
|
|
AU2003211990A1
(en)
|
2002-02-14 |
2003-09-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing solution pharmaceuticals
|
|
PT1946776T
(pt)
|
2002-02-27 |
2017-03-17 |
Immunex Corp |
Composição de tnfr-fc estabilizada compreendendo arginina
|
|
CA2481304A1
(en)
|
2002-03-27 |
2003-10-09 |
Patrick Hwu |
Method for treating cancer in humans
|
|
US20040009168A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Elizabet Kaisheva |
Multidose antibody formulation
|
|
MXPA04012116A
(es)
|
2002-06-07 |
2005-04-19 |
Zymogenetics Inc |
Uso del il-21 en cancer y otras aplicaciones terapeuticas.
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US20040022792A1
(en)
|
2002-06-17 |
2004-02-05 |
Ralph Klinke |
Method of stabilizing proteins at low pH
|
|
WO2004001007A2
(en)
|
2002-06-21 |
2003-12-31 |
Idec Pharmaceuticals Corporation |
Buffered formulations for concentrating antibodies and methods of use thereof
|
|
WO2004009479A1
(en)
|
2002-07-18 |
2004-01-29 |
Fabio Perini S.P.A. |
Storage unit for elongated products
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
RU2358763C2
(ru)
|
2003-02-10 |
2009-06-20 |
Элан Фармасьютикалз, Инк. |
Композиции иммуноглобулина и способ их получения
|
|
CN1798575A
(zh)
|
2003-04-04 |
2006-07-05 |
健泰科生物技术公司 |
高浓度抗体和蛋白制剂
|
|
CN102408483B
(zh)
|
2003-07-15 |
2016-06-08 |
安姆根有限公司 |
作为选择性ngf途径抑制剂的人抗ngf中和抗体
|
|
CN100522998C
(zh)
|
2003-10-01 |
2009-08-05 |
协和发酵麒麟株式会社 |
抗体的稳定化方法和被稳定的溶液状抗体制剂
|
|
WO2005063291A1
(ja)
|
2003-12-25 |
2005-07-14 |
Kirin Beer Kabushiki Kaisha |
抗体を含有する安定な水性医薬製剤
|
|
EP1755677A4
(en)
|
2004-06-14 |
2009-11-25 |
Medimmune Vaccines Inc |
HIGH-PRESSURE SPRAY DRYING OF BIOACTIVE MATERIALS
|
|
JP4898691B2
(ja)
|
2004-10-22 |
2012-03-21 |
ザイモジェネティクス， インコーポレイテッド |
抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
|
|
EP2192132A3
(en)
|
2005-02-08 |
2010-08-18 |
ZymoGenetics, Inc. |
Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
|
|
US7525604B2
(en)
|
2005-03-15 |
2009-04-28 |
Naxellent, Llc |
Windows with electrically controllable transmission and reflection
|
|
EP1899462B1
(en)
|
2005-07-02 |
2011-03-09 |
Arecor Limited |
Stable aqueous systems comprising proteins
|
|
WO2007006858A2
(en)
|
2005-07-12 |
2007-01-18 |
Oy Jurilab Ltd |
Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
|
|
AU2006295340B2
(en)
|
2005-08-05 |
2010-11-11 |
Amgen Inc. |
Stable aqueous protein or antibody pharmaceutical formulations and their preparation
|
|
AU2006294477A1
(en)
|
2005-09-27 |
2007-04-05 |
Source Mdx |
Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
|
|
WO2007038501A2
(en)
|
2005-09-27 |
2007-04-05 |
The Feinstein Institute For Medical Research |
Rheumatoid arthritis markers
|
|
CN101360821A
(zh)
|
2005-11-21 |
2009-02-04 |
圣诺菲·帕斯图尔有限公司 |
重组病毒的稳定制剂
|
|
BRPI0620316A2
(pt)
|
2005-12-21 |
2011-11-08 |
Wyeth Corp |
formulações de proteìnas com viscosidades reduzida e seus usos
|
|
US9084777B2
(en)
|
2005-12-28 |
2015-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing formulations
|
|
CA2638811A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
|
DE102006005094A1
(de)
|
2006-02-04 |
2007-08-09 |
Degussa Gmbh |
Titandioxid und Polycarboxylatether enthaltende Dispersion
|
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
|
JP2009530699A
(ja)
|
2006-03-15 |
2009-08-27 |
コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ |
ロール検出を備えたリモートコントロール型ポインティング技術
|
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
CA2644663A1
(en)
|
2006-03-23 |
2007-09-27 |
Kirin Pharma Kabushiki Kaisha |
Agonist antibody to human thrombopoietin receptor
|
|
WO2007110339A1
(en)
*
|
2006-03-28 |
2007-10-04 |
F. Hoffmann-La Roche Ag |
Anti-igf-1r human monoclonal antibody formulation
|
|
EP1857559A1
(en)
|
2006-05-16 |
2007-11-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A method for predicting responsiveness to TNF alpha blocking agents
|
|
BRPI0713421A2
(pt)
|
2006-06-14 |
2012-03-13 |
Imclone Systems Incorporated |
Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
|
|
CA2652924A1
(en)
|
2006-06-19 |
2007-12-27 |
Wyeth |
Methods of modulating il-22 and il-17
|
|
CN101484471B
(zh)
|
2006-06-30 |
2013-11-06 |
诺沃-诺迪斯克有限公司 |
抗-nkg2a抗体及其用途
|
|
EP2081553B1
(en)
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
|
EP2076287A2
(en)
|
2006-10-12 |
2009-07-08 |
Wyeth |
Methods and compositions with reduced opalescence
|
|
WO2008048986A2
(en)
|
2006-10-17 |
2008-04-24 |
Children's Hospital Medical Center |
Gene array technique for predicting response in inflammatory bowel diseases
|
|
JP2010508838A
(ja)
|
2006-11-09 |
2010-03-25 |
アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル（イーエヌエスエーエールエム） |
ＴＮＦ−α遮断薬に対する治療応答性の予測方法
|
|
JP2010512356A
(ja)
|
2006-12-11 |
2010-04-22 |
エフ．ホフマン−ラ ロシュ アーゲー |
非経口ａベータ抗体製剤
|
|
CA2674608A1
(en)
*
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-il-13 antibody formulations and uses thereof
|
|
WO2008104608A1
(en)
|
2007-03-01 |
2008-09-04 |
Universite Catholique De Louvain |
Method for the determination and the classification of rheumatic conditions
|
|
WO2008117513A1
(ja)
|
2007-03-23 |
2008-10-02 |
Panasonic Corporation |
導電性バンプとその製造方法および電子部品実装構造体
|
|
CA2682292A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Aqueous formulation comprising an anti-human interferon alpha antibody
|
|
GB0707938D0
(en)
|
2007-04-25 |
2007-05-30 |
Univ Strathclyde |
Precipitation stabilising compositions
|
|
WO2008132176A2
(en)
|
2007-04-27 |
2008-11-06 |
Universite Catholique De Louvain |
Method for evaluating the response of an individual to tnf blocking therapy
|
|
JP5719591B2
(ja)
|
2007-06-08 |
2015-05-20 |
バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． |
抗ｔｎｆ応答性または非応答性を予測するためのバイオマーカー
|
|
US20090208492A1
(en)
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
|
EP2170390B1
(en)
|
2007-06-14 |
2018-11-07 |
Biogen MA Inc. |
Natalizumab antibody formulations
|
|
WO2008157282A1
(en)
|
2007-06-18 |
2008-12-24 |
Genentech, Inc. |
Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
|
|
EP2170268A2
(en)
|
2007-06-25 |
2010-04-07 |
Amgen, Inc. |
Compositions of specific binding agents to hepatocyte growth factor
|
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
|
WO2009009406A1
(en)
|
2007-07-06 |
2009-01-15 |
Smithkline Beecham Corporation |
Antibody formulations
|
|
WO2009013538A2
(en)
|
2007-07-20 |
2009-01-29 |
National Institute For Bioprocessing Research And Training |
Glycosylation markers for cancer and chronic inflammation
|
|
US20100261613A1
(en)
|
2007-07-26 |
2010-10-14 |
Michael Centola |
Methods for inflammatory disease management
|
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
|
KR101615935B1
(ko)
|
2007-12-14 |
2016-04-28 |
노보 노르디스크 에이/에스 |
인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도
|
|
EP2254911B1
(en)
|
2008-02-20 |
2015-11-25 |
Novo Nordisk A/S |
Humanized anti-c5ar antibodies
|
|
WO2009120684A1
(en)
|
2008-03-25 |
2009-10-01 |
Medimmune, Llc |
Antibody formulation
|
|
EP2281000A2
(en)
|
2008-05-15 |
2011-02-09 |
Novo Nordisk A/S |
Antibody purification process
|
|
TWI451876B
(zh)
*
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
|
RU2011101969A
(ru)
|
2008-06-30 |
2012-08-10 |
Ново Нордиск А/С (DK) |
Антитела к человеческому интерлейкину-20
|
|
UA112050C2
(uk)
*
|
2008-08-04 |
2016-07-25 |
БАЄР ХЕЛСКЕР ЛЛСі |
Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
|
|
US20110159011A1
(en)
|
2008-08-28 |
2011-06-30 |
Wyeth Llc |
Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
|
|
PE20110302A1
(es)
|
2008-09-19 |
2011-05-21 |
Hoffmann La Roche |
Formulacion farmaceutica de un anticuerpo contra p-selectina
|
|
EP2196476A1
(en)
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
EP2379600B2
(en)
*
|
2008-12-22 |
2020-10-14 |
Novo Nordisk A/S |
Antibodies against tissue factor pathway inhibitor
|
|
WO2010113096A1
(en)
|
2009-03-30 |
2010-10-07 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Methods of predicting clinical course and treating multiple sclerosis
|
|
US8728730B2
(en)
|
2009-09-03 |
2014-05-20 |
Genentech, Inc. |
Methods for treating, diagnosing, and monitoring rheumatoid arthritis
|
|
US8580528B2
(en)
|
2009-10-16 |
2013-11-12 |
Stichting Vu-Vumc |
Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy
|
|
WO2011047073A2
(en)
|
2009-10-16 |
2011-04-21 |
Mayo Foundation For Medical Education And Research |
Assessing rheumatoid arthritis
|
|
BR112012021576A2
(pt)
|
2010-02-26 |
2016-10-25 |
Novo Nordisk As |
composições estáveis contendo anticorpo.
|
|
RU2012153786A
(ru)
*
|
2010-05-28 |
2014-07-10 |
Ново Нордиск А/С |
Стабильные многодозовые композиции, содержащие антитело и консервант
|
|
CA2801107A1
(en)
|
2010-06-07 |
2011-12-15 |
F. Hoffman-La Roche Ag |
Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|